Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2004-06-01
2008-11-18
Qian, Celine X (Department: 1636)
Chemistry: molecular biology and microbiology
Vector, per se
C536S023100, C536S024100
Reexamination Certificate
active
07452717
ABSTRACT:
Polynucleotides encoding carboxylesterase enzymes and polypeptides encoded by the polynucleotides which are capable of metabolizing a chemotherapeutic prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing tumor cells to a prodrug chemotherapeutic agent and inhibiting tumor growth with this enzyme are also provided. In addition, screening assay for identification of drugs activated by this enzyme are described.
REFERENCES:
Alexson et al (The Journal of Biological Chemistry, 1994. vol. 269, No. 25, pp. 17118-17124).
Senter et al (Cancer Research, 1996. vol. 56, pp. 1471-1474).
Bello-Fernandez et al (Proceedings of National Academy of Science USA, 1993. vol. 90, pp. 7804-7808).
Munger et al (J. Biol.Chem. vol. 266, No. 28, pp. 18832-18838, 1991).
Genbank M73499, 1993.
Bello-Fernandez, C., et al., “The ornithine decarboxylase gene is a transcriptional target of c-Myc”, 1993Proc. Natl. Acad. Sci. USA90:7804-7808.
Brodeur, G.M., et al., “Biology and Genetics of Human Neurblastomas”, 1997J. Ped. Hematol. Oncol. 19:93-101.
Dachs et al., “Targeting Gene Therapy to Cancer: A Review”, 1997Oncol. Res. 9:313-325.
Davis et al., “Current progress in the gene therapy of cancer”, 1996Current Opinion in Oncology8:499-508.
Field, et al., “Elevated expression of thec-myconcoprotein correlates with poor prognosis in head and neck squamous cell carcinoma”, 1989Oncogene4:1463-1468.
Haaz, M.C., et al., “Metabolism of Irinotecan (CPT-11) by Human Hepatic Microsomes: Participation of Cytochrome P-450 3A and Drug Interactions1”, 1998Cancer Res. 58:468-472.
Hanania et al., “Recent Advances in the Application of Gene Therapy to Human Disease”, 1995Am. Jour. Med. 99:537-552.
Houghton, P.J., et al., “Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors”, 1995 36:393-403.
Houghton, P.J., et al., “Therapeutic Efficacy of the Topoisomerase I Inhibitor 7-Ethyl-10-(4-(1-piperidino)-1-piperidino)-carbonyloxy-camptothecin against Human Tumor Xenografts:Lack of Cross-Resistance in Vivo in Tumors with Acquired Resistance to the Topoisomerase I Inhibitor 9-Dimethylaminomethyl-10-hydroxycamptothecin1”, 1993 53:2823-2829.
Hsiang, Y.-H. et al., “Arrest of Replication Forks by Drug-stabilized Topoisomerase I-DNA Cleavable Complexes as a Mechanism of Cell Killing by Camptothecin1”, 1989Cancer Res. 49:5077-5082.
Humerickhouse et al., “Characterization of CPT-11 Hydrolysis by Human Liver Carboxylesterase Isoforms hCE-1 and hCE-21”, 2000Cancer Res. 60:1189-1192.
Johnson et al., “Current therapy for cutaneous melanoma”, 1995J. Am. Acad. Derm. 32(5):689-707.
Kaneda, N. et al., “Metabolism and Pharmacokinetics of the Camptothecin Analogue CPT-11 in the Mouse”, 1990Cancer Res. 50:1715-1720.
Kawasaki, -H. et al., “Specific Regulation of Gene Expression by Antisense Nucleic Acids: A Summary of Methodologies and Associated Problems”, 1996Artif. Organs20(8):836-848.
Kawato, Y. et al., “ Intracellular Roles of SN-38, a Metabolite of the Camptothecin Derivative CPT-11, in the Antitumor Effect of CPT-11”, 1991Cancer Res. 51:4187-4191.
Korza, G. and J. Ozols, “Complete Covalent Structure of 60-kDa Esterase Isolated from 2,3,7,8-Tetrachlorodibenzo-p-dioxin-induced Rabbit Liver Microsmoes” 1988J. Biol. Chem. 263:3486-3495.
Kumagai, T. et al., “Eradication of Myc-overexpressing Small Cell Lung Cancer Cells Transfected with Herpes Simplex Virus Thymidine Kinase Gene Containing Myc-Max Response Elements1”, 1996Cancer Res. 56(2):354-358.
Leinwerber, F.J., “Possible Physiological Roles of Carboxylic Ester Hydrolases”, 1987Drug Metabl. Rev. 18:379-439.
Lutz et al., “Conditional expression of N-mycin human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and acccelerates progression into S-phase early after mitogenic stimulation of quiescent cells”, 1996Oncogene13:803-812.
Matthay; K.E., “Neuroblastoma:Biology and Therapy”, 1997Oncology11:1857-1875.
Matthay, K.E., et al., “Patterns of Relapse After Autologous Purged Bone Marrow Transplantation for Neuroblastoma: A Childrens Cancer Group Pilot Study”, 1993J. Clin. Oncol. 11:2226-2233.
Nagai, M.A., et al., “Association of Genetic Alterations ofc-myc, c-fos, and c-Ha-rasProto-Oncogenes in Colorectal Tumors”, 1992Dis. Colon Rectum35:444-451.
Orian, J.M., et al., “Overexpression of multiple oncogenes related to histological grade of astrocytic glioma”, 1992Br. J. Cancer66:106-112.
Raschella, G., et al., “Lack of Correlation between N-mycand MAX Expression in Neuroblastoma Tumors and in Cell Lines: Implication for N-myc-MAX Complex Formation1”, 1994Cancer Res. 54:2251-2255.
Rill, D.R., et al., “Direct Demonstration That Autologous Bone Marrow Transplantation for Solid Tumors Can Return a Multiplicity of Tumorigenic Cells”, 1994Blood84:380-383.
Riou, G., et al., “C-mycProton-Oncogene Expression and Prognosis in Early Carcinoma of the Uterine Cervix”, 1987Lancet2:761-763.
Rivory, et al., “Identification and Properties of a Major Plasma Metabolite of Irinotecan (CPT-11) Isolated from the Plasma of Patients1”, 1996Cancer Res. 56:3689-3694.
Rivory, L.P., et al., “Pharmacokinetic Interrelationships of Irinotecan (CPT-11) and Its Three Major Plasma Metabolites in Patients Enrolled in Phase I/II Trials1”, 1997Clin. Cancer Res. 56:3689-3694.
Roth and Cristiano, “Gene Therapy for Cancer: What Have We Done and Where Are We Going?”, 1997J. Natl. Canc. Inst. 89(1):21-39.
Rowinsky, E.K., et al., “Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administred as a Ninety-Minute Infusion Every 3 Weeks1”, 1994Cancer Res. 54:427-436.
Satoh, T., et al., “Metabolic Activation of CPT-11, 7-Ethyl-10-[4-1(piperidino)-1-piperidino] carbonyloxycamptothecin, a Novel Antitumor Agent, by Carboxylesterase” 1994Biol. Pharm. Bull. 17:662-664.
Senter, P.D., et al., “The Role of Rat Serum Carboxylesterase in the Activation of Paclitaxel and Camptothecin Prodrugs”, 1996Cancer Res, 56:1471-1474.
Tanizawa, A., et al., “Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials”, 1994J. Natl. Cancer Intst, 86:836-842.
Tsuji, T., et al., “CPT-11 Converting Enzyme from Rat Serum:Purification and Some Properties”, 1991J. Pharmacobio. Dynamics1:341-349.
Yamada, H., et al., “Amplifications of Both c-Ki-rasWith a Point Mutation andc-mycin a Primary Pancreatic Cancer and its Metastatic Tumors in Lymph Nodes”, 1996Jpn. J. Cancer Res. 77:370-375.
Yang, N.S., “Gene Transfer into Mammalian Somatic Cells In Vivo”, 1992Crit. Rev. Biotechnol. 12:335-356.
Humerickhouse et al., “Characterization of CPT-11 Hydrolysis by Human Liver Carboxylesterase Isoforms hCe-1 and hCE-21”, Cancer Research 2000 60:1189-1192.
Pindel et al., “Purification and Cloning of a Broad Substrate Specificity Human Liver Carboxylesterase That Catalyzes the Hydrolysis of Cocaine and Heroin”, J. Biol. Chem. 1997 272(23):14769-14775.
Danks Mary K.
Houghton Peter J.
Potter Philip M.
Licata & Tyrrell P.C.
Qian Celine X
St. Jude Children's Research Hospital
LandOfFree
Compositions and methods for sensitizing and inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for sensitizing and inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for sensitizing and inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045318